Trial Profile
A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 17 Oct 2023 Planned End Date changed from 1 Nov 2023 to 1 Jan 2024.
- 30 Dec 2022 Planned End Date changed from 1 Dec 2023 to 1 Nov 2023.